Skip to main content
. 2016 Oct 18;7(47):76934–76943. doi: 10.18632/oncotarget.12734

Figure 2. Impact of beta-2 microglobulin on the prediction of overall survival in the low/low-intermediate and high-intermediate/high risk groups by the IPI and NCCN-IPI in the training cohort.

Figure 2

(A) Low/low-intermediate risk groups by the IPI. (B) High-intermediate/high risk groups by the IPI. (C) Low/low-intermediate risk groups by the NCCN-IPI. (D) High-intermediate/high risk groups by the NCCN-IPI.